In chronic hepatitis C virus (HCV) infection, it has previously been shown that patients with strong ISG‐signatures have a lower chance of responding to treatment with IFNα, clearly demonstrating the in vivo relevance of interferon pathway desensitization (Chen et al, 2005). This evidence concerns the gene IFNA2 and chronic hepatitis.